

Serena Zacchigna, MD PhD
Group Leader, Cardiovascular Biology
ICGEB and University of Trieste, Italy


zacchign@icgeb.org
http://www.icgeb.org



Trieste

Genetic Engineering


Our body is made up of cells




The human body:

~1x10¹⁴ (100 trillion) cells


200+ different cell types



Cell function is exerted by proteins



Flow of genetic information




DNA the molecule of life

Trillions of cells

Each cell:

- 46 human chromosomes
- 2 meters of DNA
- 3 billion DNA subunits (the bases: A, T, C, G)
- Approximately 20,000 genes code for proteins that perform most life functions



2 December 1999 International weekly journal of science

nature

The first human chromosome sequence

The Sequence of the Human Genome

J. Craig Venter,¹ Mark D. Adams,¹ Eugene W. Myers,¹ Peter W. Li,¹ Richard J. Mural,¹ Gregor C. Sutton,¹ Hamilton O. Smith,¹ Mark Yandell,¹ Cheryl A. Evans,¹ Robert A. Holt,¹ Jonathan D. Gordon,¹ Peter Amanalidis,¹ Richard M. Balaban,¹ Daniel H. Bason,¹ Jennifer Russ Wortman,¹ Qing Zhang,¹ Chiwaya D. Kwoh,¹ Xianggen H. Zhang,¹ Lin Chen,¹ Marian Shipkova,¹ Coughlan Subramanian,¹ Paul D. Thomas,¹ Jinghui Zhong,¹ George L. Kaber Mikkil,¹ Catherine Nelson,¹ Samuel Broder,¹ Andrew G. Clark,¹ Joe Neidus,¹ Victor A. McKusick,¹ Herton Zlotnik,¹ Arnold J. Levine,¹ Richard J. Roberts,¹ Mel Simons,¹ Carolyn Steyger,¹ Michael Husarek,¹ Randall Belmont,¹ Arthur Doolittle,¹ Ian Dunham,¹ David Faulstich,¹ Michael Flanagan,¹ Liliana Flores,¹ Aaron Halpern,¹ Siddhar Hanumanthalli,¹ Saul Kravitz,¹ Samuel Levy,¹ Clark Micharyn,¹ Scott Rothenberg,¹ Karin Rostrogren,¹ Jane Aho-Teittinen,¹ Ellen Beaudry,¹ Kendra Biddis,¹ Vivian Bonaldi,¹ Rhonda Brandon,¹ Michela Cargill,¹ Ishwar Chandrasekharan,¹ Susana Charlab,¹ Kadi Chatterjee,¹ Zhaoping Deng,¹ Valerina Di Francesco,¹ Patrick Dunn,¹ Karen Eilbeck,¹ Carlos Evangelista,¹ Andrei E. Gabrielian,¹ Weiqiu Gu,¹ Wangmao Gu,¹ Fangchang Gong,¹ Zhiping Gu,¹ Ping Guo,¹ Thomas J. Heinzel,¹ Maureen E. Higgins,¹ Rui-Ru Ji,¹ Zhanyi Ke,¹ Karen A. Ketchum,¹ Zhongping Jai,¹ Yifeng Jai,¹ Chuanxi Li,¹ Jiyun Li,¹ Yang Cheng,¹ Xiangping Liu,¹ Fu Lin,¹ Gernady V. Markov,¹ Natalia Mikhlin,¹ Helen M. Moore,¹ Ashwinbharan K. Nakh,¹ Vukobur A. Neryan,¹ Renee Nickson,¹ Deborah Novitskaya,¹ Douglas B. Rausch,¹ Steven Leeburg,¹ Wei Shao,¹ Bixiong Shan,¹ Jingtao Sun,¹ Zhao Yuan Wang,¹ Aihui Wang,¹ Xin Wang,¹ Jian Wang,¹ Ming-Hui Wei,¹ Ben Wilton,¹ Chaoxin Xian,¹ Chuanhua Yao,¹ Aimin Yan,¹ Jun Ye,¹ Ming Zhan,¹ Weiqing Zhang,¹ Hongyue Zhang,¹ Qi Zhan,¹ Lianhong Zheng,¹ Fei Zhang,¹ Weiyang Zhong,¹ Shiqiang C. Zhu,¹ Shuying Zhao,¹ Dennis Gilbert,¹ Suzanne Baumhueter,¹ Gene Spier,¹ Christine Carter,¹ Nathaniel Cavalli,¹ Trevor Wandegert,¹ Terese Ali,¹ Huijin An,¹ Adarshika Awa,¹ Daniela Badalini,¹ Holly Baden,¹ Mary Bernstead,¹ Ian Barrow,¹ Karen Beeson,¹ Dana Basam,¹ Amy Carter,¹ Angela Carter,¹ Ming Lai Cheng,¹ Liu Curry,¹ Steve Danaher,¹ Lionel Daverny,¹ Raymond Deslats,¹ Susanne Dietz,¹ Felicitia Douvan,¹ Lisa Doup,¹ Steven Ferreira,¹ Naha Garg,¹ Andrea Glöckmann,¹ Brit Hart,¹ Jason Haynes,¹ Charles Haynes,¹ Cheryl Heiner,¹ Suzanne Hedden,¹ Damon Heinen,¹ Jarrett Houch,¹ Timothy Hornlund,¹ Chiyone Inagawa,¹ Jeffrey Johnson,¹ Francis Kalish,¹ Lindsey Kline,¹ Shaoh Kodera,¹ Amy Love,¹ Felicia Mann,¹ David May,¹ Steven McCandless,¹ Tina McQuinn,¹ Ivy McPherson,¹ Hua Mei,¹ Linda Moy,¹ Brian Murphy,¹ Keith Nelson,¹ Cynthia Pflanzl,¹ Eric Pratts,¹ Vinita Puri,¹ Hina Qureshi,¹ Matthew Reardon,¹ Robert Rodriguez,¹ Yu-Hsiu Rogers,¹ Deanna Romblad,¹ Rob Kunkel,¹ Richard Scott,¹ Cynthia Sitter,¹ Michelle Smallwood,¹ Eric Stewart,¹ Renee Strong,¹ Ellen Suik,¹ Reginald Thomas,¹ Ni Ni Tin,¹ Seokyeo Yoo,¹ Claire Vash,¹ Gary Wang,¹ Jeremy Waller,¹ Sherita Williams,¹ Melissa Williams,¹ Sandra Wisniewski,¹ Emily Wilson-Dunn,¹ Karoline Wolfe,¹ Jayshree Zaveri,¹ Ramona Zaveri,¹ Joseph F. Abril,¹ Rodger Gough,¹ Michael J. Campbell,¹ Kimmen V. Sijlander,¹ Brian Karkas,¹ Ansh Kishore,¹ Haoyue He,¹ Betty Lazarus,¹ Thomas Hartigan,¹ Agnese Marchetti,¹ Karen Drenth,¹ Anushya Mungamuru,¹ Nan Cao,¹ Shiqi Sata,¹ Vinod Balra,¹ Surin Intra,¹ Russ Lippert,¹ Russell Schwartz,¹ Brian Wilton,¹ Shira Frankel,¹ David Rubin,¹ David Bera,¹ James Braxton,¹ Louis Bick,¹ Marcello Cambiata,¹ John Caron-Simon,¹ Paris Caik,¹ Yen-Hsi Chiang,¹ My Coyne,¹ Carl Dabbs,¹ Anne Delattre-Hays,¹ Maria Dembrak,¹ Michael Donnelly,¹ Dale Ely,¹ Shiva Eshagham,¹ Carl Fisher,¹ Harold Gao,¹ Stephen Glassner,¹ Kenneth Glasser,¹ Anna Glöckl,¹ Mark Gorenkhan,¹ Ken Graham,¹ Barry Grogman,¹ Michael Harris,¹ Jeremy Hall,¹ Scott Henderson,¹ Jeffrey Hoover,¹ Donald Jennings,¹ Catherine Jordan,¹ James Jordan,¹ Leonard Jordan,¹ Cheryl Kraft,¹ Alexander Levtchik,¹ Mark Lewis,¹ Xianglin Liu,¹ John Lopez,¹ Daniel Ma,¹ William Mei,¹ Joe McMichael,¹ Sean Murphy,¹ Matthew Neuman,¹ Nigam Nigam,¹ Ngoc Nguyen,¹ John O'Connell,¹ Sue Pan,¹ Jim Peck,¹ Marshall Peterson,¹ William Reme,¹ Robert Sanders,¹ John Michael Simpson,¹ Thomas Smith,¹ Arlan Sprague,¹ Timothy Stockwell,¹ Russell Tamm,¹ Hai Wang,¹ Haiyan Wang,¹ David Wu,¹ Mitchell Wu,¹ Ashley Xia,¹ Ai Zhan,¹ Xian

Climate change
Thermohaline trigger

Intermolecular energetics
Good vibrations

Impacts of foreseeable science
Supplement with this issue


New on the market
Lasers

16 FEBRUARY 2001 VOL 291 SCIENCE www.nature.com



A COMPLETE HUMAN GENOME IS CLOSE: HOW THE GAPS WERE FILLED

Researchers added 200 million DNA base pairs and 115 genes – but they’ve yet to finish the Y chromosome.



- Telomere-to-Telomere (T2T) Consortium, 30 institutions
- 115 new genes that code for proteins, for a total of 19,969
- cells from a hydatidiform mole, a tissue that forms in humans when a sperm inseminates an egg with no nucleus (chromosomes only from the father)
- new sequencing technology, which uses lasers to scan long stretches of DNA isolated from cells
- T2T-CHM13 represents only one person's genome

The human genome

Number of chromosomes: 46
 Size of the human genome: $\sim 3 \times 10^9$ bp
 Number of genes: $\sim 20,000$

Genes: 30%
 Extragenic DNA: 70%
 Coding regions: <2% (!)
 Non coding regions: >98%

The main genomes sequenced before the human genome

1984	Bacteriophage lambda	0.049	
1991	Smallpox virus	0.186	187
1995	Haemophilus influenzae	1.8	1,740
1996	Saccharomyces cerevisiae	12.1	6,000
1997	Helicobacter pylori	1.67	1,590
1997	Escherichia coli	4.64	4,288
1998	Coenorhabditis elegans	97	13,000
2000	Drosophila melanogaster	180	13,000
2000	Pseudomonas aeruginosa	6.3	6,000 ?
2000	Arabidopsis thaliana	100	25,000
2001	Homo sapiens sapiens	2.9-10	30-35,000
	Mus musculus	SIZE	NUMBER OF GENES
	Plasmodium falciparum (chr 2 and 3)		

The SNP Consortium

The SNP Consortium

The Wellcome Trust has invested £9 million in the SNP Consortium - a £30 million collaboration between the Trust, 13 pharmaceutical and technological companies and leading academic centres to create a high-quality map of genetic markers. Over the next two years, the Consortium aims to identify 300 000 single nucleotide polymorphisms (SNPs or 'snips') in the human genome, variations that could be markers for a susceptibility to diseases such as Alzheimer's, diabetes or cancer.

The information gathered by the SNP Consortium will be made publicly available to researchers over the Internet. With the SNP map to hand, researchers hope to be able to devise new medical treatments, and treatments specifically tailored to individuals.

Take the short cut: A brief guide to SNPs
 Everything you need to know about SNPs - what they are and why they are useful.

Read the article
 The cutting edge: SNPs and their medical application (adapted from [Wellcome News Issue 20](http://wellcome-trust.org), Q3 1999)

Frequently asked questions about the SNP Consortium
 All you need to know about the Consortium.

Members of the SNP Consortium
 The pharmaceutical company partners and the sequencing centres involved.

The SNP Consortium website
<http://snp.csf.org/>

Press release
 Consortium of pharmaceutical companies and the Wellcome Trust fund creation of public database of gene markers.

Confrontando il DNA di due individui sani si riconoscono circa 3 milioni di differenze (1 nucleotide ogni mille)

Approximately 3×10^6 differences exist between the genomes of two healthy individuals (1 every 1000 nucleotides)

International HapMap Project

Home | About the Project | Data | Publications | Tutorial


What is the HapMap? Origins of Haplotypes Health Benefits Populations Sampled Ethical Issues Contact Us Community Advisory Groups (CAG) Data Release Policy Guidelines For Data Use Guidelines For Referring to HapMap Populations

About the HapMap


The International HapMap Project is a multi-country effort to identify and catalog genetic similarities and differences in human beings. Using the information in the HapMap, researchers will be able to find genes that affect health, disease, and individual responses to medications and environmental factors. The Project is a collaboration among scientists and funding agencies from Japan, the United Kingdom, Canada, China, Nigeria, and the United States. (See Participating Groups and Initial Planning Groups) All of the information generated by the Project will be released into the public domain.

The goal of the International HapMap Project is to compare the genetic sequences of different individuals to identify chromosomal regions where genetic variants are shared. (See What is the HapMap?) By making this information freely available, the Project will help biomedical researchers find genes involved in disease and responses to therapeutic drugs. (See How Will the HapMap Benefit Human Health?) In the initial phase of the Project, genetic data are being gathered from four populations with African, Asian, and European ancestry. Ongoing interactions with members of these populations are addressing potential ethical issues and providing valuable experience in conducting research with identified populations.

Public and private organizations in six countries are participating in the International HapMap Project. Data generated by the Project can be downloaded with minimal constraints. (See Data Release Policies.) The Project officially started with a meeting in October 2002 (<http://genome.gov/10005336>) and is expected to take about three years.





Kary B. Mullis




Applications of PCR:

1. Detection of pathogens
2. Diagnosis of genetic diseases
3. Identification of criminals, forensic medicine, paternity test
4. Monitoring gene expression
5. Evolutionary tracing
6. DNA cloning



The molecular bases of DNA replication




Taq polymerase is a DNA polymerase derived from Thermus Aquaticus


Thermus Aquaticus is a Gram Positive bacterium that is classified under a group called thermophiles. Thermophiles are defined as organisms that thrive and reproduce at temperatures that are above 45 Degrees Celsius. Specifically, Thermus Aquaticus optimally thrives and reproduces at 70 degrees celsius.






PCR amplification




PCR cycles







Gel Electrophoresis Separates DNA Molecules of Different Sizes



The story of the human gene defective in alkaptonuria



Embryo selection



OMIM Online Mendelian Inheritance in Man Johns Hopkins University

Search OMIM for [] [Go] [Clear]

Display Detailed Show 20 Send to Text

107850 ARM FOLDING PREFERENCE

TEXT

If in folding his arms the right arm is on top, the person is classed R. Hand clasping (139800) is a comparable trait. Falk and Ayala (1971) concluded that, although both traits are heritable to a significant extent, a simple mendelian hypothesis is not tenable. Feronato et al. (1974) found no significant correlation between parents and children for arm folding preference, i.e., right arm or left arm on top.

REFERENCES

- Falk, C. T.; Ayala, F. J.: Genetic aspects of arm folding and hand clasping. *Am. J. Hum. Genet.* 15: 241-247, 1971.
- Feronato, S.; Thomas, D.; Sadava, D.: Preferences for handedness, arm folding, and hand clasping in families. *Hum. Hered.* 24: 345-351, 1974. PubMed ID: 4461659


CREATION DATE

Victor A. McKusick : 6/4/1986

EDIT HISTORY

mimadm : 4/9/1994
 supermin : 3/16/1992
 supermin : 3/20/1990
 ddp : 10/26/1989
 marie : 3/25/1988
 root : 1/12/1988

Copyright © 1966-2003 Johns Hopkins University



OMIM Online Mendelian Inheritance in Man Johns Hopkins University

Search OMIM for [] [Go] [Clear]

Display Detailed Show 20 Send to Text

129100 EARS, ABILITY TO MOVE

TEXT

Linder (1949) found a frequency of the trait among parents and sibs of probands, leading to the idea that the ability is inherited as a somewhat irregular dominant. In 5 of 24 cases both parents lacked the trait. In Barcelona, Hernandez (1980) found that 19.9% of men and 9.57% of women could move their ears. In males, there was an association with tongue rolling (189300).

REFERENCES

- Hernandez, M.: La movilidad del pabellon auditivo. *Trab. Antropol.* XVIII(4): 199-203, 1980.
- Linder, L.: The ability to move the ears. *Hereditas* 35 (suppl.): 620-621, 1949.

CREATION DATE

Victor A. McKusick : 6/4/1986

EDIT HISTORY

mimadm : 6/25/1994
 supermin : 3/16/1992
 supermin : 3/20/1990
 ddp : 10/26/1989
 marie : 3/25/1988
 reenie : 6/4/1986

Copyright © 1966-2003 Johns Hopkins University



news and views

Mapping genes for human personality

C. Robert Cloninger¹, Rolf Adolphsson² & Nenad M. Svrakic¹


Nature Genetics 12, 3-4 (1996)

Temperament: dynamic organization of the psychobiological systems that regulate automatic responses to emotional stimuli

Four temperament domains:
 Novelty seeking
 Harm avoidance
 Reward dependence
 Persistence

e.g.: **extravert with mature creative character:**
 HIGH Novelty seeking
 LOW Harm avoidance (optimistic)
 HIGH Reward dependence (sociable)
 LOW Persistence

e.g.: **antisocial alcoholics:**
 LOW Novelty seeking
 ~ Harm avoidance (optimistic)
 LOW Reward dependence (sociable)
 ~ Persistence



10% of variation in Novelty seeking is accounted for by a polymorphism of the D4 dopamine receptor gene (D4DR)

Long alleles: HIGH Novelty seeking (exploratory, thrill seeking, excitable)
 Short alleles: LOW Novelty seeking (deliberate, rigid, orderly)

Ebstein et al. *Nature Genetics* 12, 78-80 (1996)
 Benjamin et al. *Nature Genetics* 12, 81-84 (1996)





Meeting American Association of Physical Anthropologists

Tracking the Evolutionary History of a "Warrior" Gene

For males, a bit of aggression and risk-taking can earn rewards—but too much aggression can lead to violence. Aggression, only death, and the worst of all is evolutionary terms, offspring. Not everyone has the same level of aggression, and in the genes of our primate cousins, the MAOA gene, it's all about balancing act. In the genes of our primate cousins, the MAOA gene, it's all about balancing act. In the genes of our primate cousins, the MAOA gene, it's all about balancing act.



Chimpanzee Gang Warfare

Primateologists have long known that chimpanzees can be diverse. Bands of males entirely lead by the borders of their territory in each and separate domains, and why do males of the troop—who cooperate fiercely with each other in the time—seem to cooperate while on patrol? The answer, it seems, may be a rich menagerie.



Genetic variation in the vasopressin receptor 1a gene (AVPR1A) associates with pair-bonding behavior in humans

Hasse Walum^{1,2}, Lars Westberg¹, Susanne Henningsson¹, Jenae M. Neiderhiser³, David Reiss⁴, Wilmar Igl¹, Jody M. Ganiban⁵, Erica L. Spotts¹, Nancy L. Pedersen⁶, Elias Eriksson¹, and Paul Lichtenstein¹

¹Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Box 281, S-171 77 Stockholm, Sweden; ²Department of Neuroscience and Physiology, University of Gothenburg, Box 431, S-405 30 Gothenburg, Sweden; ³Department of Psychology, Pennsylvania State University, University Park, PA 16802; ⁴Yale Child Study Center, Yale University, New Haven, CT 06520; ⁵Department of Psychology, The George Washington University, Building GG, 2125 G St NW, Washington, DC 20052; and ⁶Behavioral and Social Research Program, National Institute on Aging, Bethesda, MD 20892-9205

RS3 allele "334" present in 2 our 5 men
PARTNER BONDING: Renders men distant and disagreeable rather than emotionally close and available

MARITAL STATUS: Is predictive of men not getting married (32% of the men with two alleles were living to women without getting married vs. 17% of men without any allele)

PERCEIVED MARITAL PROBLEMS: Men with two copies of the allele had twice the risk of experiencing marital dysfunction with a threat of divorce

Table 3. Effect of 0, 1 or 2 R334 alleles on male reports on the Partner Bonding Scale, marital crisis, and marital status.

Measure	Number of R334 alleles			df	F	P
	0	1	2			
Partner Bonding Scale	48.0 (8.50)	46.3 (8.16)	45.5 (8.71)	2, 143	8.40	0.0004
Frequency and column-wise percentage of subjects reporting marital crisis/threat of divorce in the three groups						
Have you experienced marital crisis or threat of divorce during the last year?						
No	469 (85%)	277 (84%)	27 (56%)	2, 143	5.00	0.008
Yes	81 (15%)	51 (16%)	14 (34%)			
Frequency and column-wise percentage of subjects being married or cohabiting in the three groups						
Marital status	457 (83%)	275 (84%)	28 (68%)	2, 143	4.36	0.01
Cohabiting	98 (17%)	52 (16%)	13 (32%)			

Values for the Partner Bonding Scale are means with standard deviation in brackets.

SMITTEN DAILY SEX & RELATIONSHIPS BLOG

See all blog posts
Does Your Man Have "The Cheating Gene?"
Thursday, 09/ 4/2008 at 11:02 AM Comments (12)

V1aR gene RS3 allele 334



the "cheating gene"
the "infidelity gene"
the "divorce gene"

the "commitment gene"
the "bonding gene"
the "monogamy gene"

My grandfather just wasn't "the cheating type." Although he was a tall, dark and handsome fighter pilot in WWII, he wouldn't have cheated on my grandmother in a million years. I figured he was just a great guy. But new research shows that his good behavior might have been in his genes. And other men, because of their genes, may cheat more often!

Swedish scientists have just made a shocking discovery: Two out of every five men (that's a lot!) carry a gene variant, known as an allele. Men with one or two of the alleles were found in the study to be more likely to have marital problems and get divorced than other men. Women involved with these men were also more likely describe their partners as distant and disagreeable.

Yikes, that's pretty heavy news. Have you met guys who seem like the "cheating type"? On the flip, have you met guys who seem destined to be faithful? If you're dating someone, would you want to test him for the gene before walking down the aisle? And what if you found out he had it—would that change your mind about marrying him? Tell me your thoughts, ladies!

Welcome to Genesis Biolabs
http://www.genesisbiolabs.com/ruthlessness.php

Genesis Biolabs

Home | Paternity Test | Genetic Tests | Other Products | What's New?

Home | Bonding Gene | Legacy Sensitivity | Other Tests

Pre-marital genetic screening usually includes tests for rare genetic disorders.
Genesis Biolabs offers the first genetic screen for marital success!*

Screening for AVPR1a, known alternately as the "ruthlessness" gene or the "bonding" gene, is likely an indicator of marital happiness. Marriages born out of mutual respect and mutual interest rather than self-interest are much more likely to succeed and probably less likely to end in divorce. Is your fiancé just after your money? Those with the "ruthlessness" gene may very well be. Those with the altruistic version of AVPR1a probably aren't. Ruthless people will lie, cheat and steal to get what they want. Genetics may not be a guaranteed indicator of human behavior and motivation (genetics is only one half of the nature vs. nurture debate) but genes don't lie. Before you make a lifetime commitment, have your fiancé tested.

"Ruthlessness/Bonding" Gene Test. I have read and agree to the [Terms of Use](#)

Order a Bonding Gene Test : \$99

Buy Now

Autobioscience Simple Checkout

You will receive 1 mouth swab and collection tube per test, in a return package, along with specific instructions on how to collect the samples. Ask your fiancée, significant other, business partner and/or elected representative to get these genetic tests done as soon as possible. This is for informational purposes only and is not a medical diagnosis. Consult with your doctor.

The heritability of happiness
Dean H. Hamer
Nature Genetics 14, 125-126 (1996)

Longitudinal study of 1,380 pairs of twins born between 1936-1955. Measure of happiness by the Well Being scale of the Multidimensional Personality Questionnaire

Correlation for Well Being scale:

If twins grew up together:
0.44 for monozygotic twins
0.08 for dizygotic twins

If twins were separated at infancy:
0.52 for monozygotic twins
0.02 for dizygotic twins

After 5 years:
cross-time correlation: 0.5 for both type of twins
cross-time correlation: 0.40 for monozygotic twins
cross-twin correlation: 0.07 for dizygotic twins


40-50% of happiness heritable
0% due to shared environment
including parenting style, socioeconomic status and educational system

50-60% due non shared environment
including unique life experiences

0.4/0.5 = 80% of stable happiness is genetic

Lykken and Tellegen. Psychol. Sci. 7, 186-189 (1996)


"Hello, said Mr. Happy. "I'm Mr. Happy."
"Oh, are you indeed?"
scuffed the person who looked like Mr. Happy but wasn't. "Well, my name is Mr. Miserable, and I'm the most miserable person in the world."
"Why are you so miserable?" asked Mr. Happy.
"Because I am," replied Mr. Miserable.



L'infarto del miocardio in soggetti giovani (prima dei 40 anni)






Meccanismi molecolari della crescita tumorale



POLIMORFISMI/ MUTAZIONI PROTETTIVI:

CCR5 E HIV

ANEMIA
FALCIFORME
E MALARIA



Human Identity Testing

- Forensic cases -- matching suspect with evidence
- Paternity testing -- identifying father
- Historical investigations
- Missing persons investigations
- Mass disasters -- putting pieces back together
- Convicted felon DNA databases

Sources of Biological Evidence


- Blood
- Semen
- Saliva
- Urine
- Hair
- Teeth
- Bone
- Tissue



Brief History of Forensic DNA Typing


- 1980 - Ray White describes first polymorphic RFLP marker
- 1985 - Alec Jeffreys discovers multilocus VNTR probes
- 1985 - first paper on PCR
- 1988 - FBI starts DNA casework
- 1991 - first STR paper
- 1995 - FSS starts UK DNA database
- 1998 - FBI launches CODIS database

Restriction nucleases




Restriction Fragment Length Polymorphism (RFLP)

Polymorphism refers to the DNA sequence variation between individuals of a species. If the sequence variation occurs at the restriction sites, it could result in RFLP. The most well known example is the RFLP due to β globin gene mutation.




Restriction Fragment Length Polymorphism (RFLP) resulting from β -globin gene mutation. In the normal cell, the sequence corresponding to 5th to 7th amino acids of the β -globin peptide is CCTGAGAG, which can be recognized by the restriction enzyme *Mst*II. In the sickle cell, one base is mutated from A to T, making the site unrecognizable by *Mst*II. Thus, *Mst*II will generate 0.2 kb fragments in the normal cell, but generate 1.4 kb fragment in the sickle cell.

RFLP



Short Tandem Repeats (STRs)




the repeat region is variable between samples while the flanking regions where PCR primers bind are constant

Homozygote = both alleles are the same length

Heterozygote = alleles differ and can be resolved from one another

13 CODIS Core STR Loci with Chromosomal Positions



Real Time PCR


Fluorogenic 5' nuclease chemistry

- 1. Polymerization:** A fluorescent reporter (R) dye and a quencher (Q) are attached to the 5' and 3' ends, respectively, of a TaqMan probe.
- 2. Strand displacement:** When the probe is intact, the reporter dye emission is quenched.
- 3. Cleavage:** During each extension cycle, the DNA polymerase cleaves the reporter dye from the probe.
- 4. Polymerization completed:** Once separated from the quencher, the reporter dye emits its characteristic fluorescence.


SYBR[®] Green I dye assay chemistry

- 1. Reaction set-up:** The SYBR[®] Green I dye fluoresces when bound to double-stranded DNA.
- 2. Denaturation:** When the DNA is denatured, the SYBR[®] Green I dye is released and the fluorescence is drastically reduced.
- 3. Polymerization:** During extension, primers anneal and PCR product is generated.
- 4. Polymerization complete:** SYBR[®] Green I dye binds to the double-stranded product, resulting in a net increase in fluorescence detected by the TSG system.

The amplification plot



Gene expression analysis



Multiplex PCR

- Over 10 Markers Can Be Copied at Once
- Sensitivities to levels less than 1 ng of DNA
- Ability to Handle Mixtures and Degraded Samples
- Different Fluorescent Dyes Used to Distinguish STR Alleles with Overlapping Size Ranges

DNA Use in Forensic Cases

- Most are rape cases (>2 out of 3)
- Looking for match between evidence and suspect
- Must compare victim's DNA profile

Challenges

- Mixtures must be resolved
- DNA is often degraded
- Inhibitors to PCR are often present




Highly Multiplexed Assays for Measuring Polymorphisms on the Y-Chromosome

International Society of Forensic Genetics

August 30, 2001

John Butler Rich Schoske Pete Vallone


There is a growing interest in the Y-chromosome to aid forensic and paternity testing... (>50 presentations here at ISFG on Y markers)



European Y-STR Haplotype Reference Database

Created by Sascha Willuweit and Lutz Roewer
 Institute of Legal Medicine, Humboldt-Universität Berlin, Germany
 in cooperation with Michael Krawczak (Cardiff), Manfred Kayser (Leipzig) and Peter de Knijff (Leiden)


This database has been accessed **14809** times since 01/01/2000. Last haplotype entry **3/26/2001**
 Current state of the database: **45** European population samples
5529 minimal haplotypes, **2196** of these are extended haplotypes




n = 850 mt-DNA D-Loop sequences (data kindly provided by the Institute of Legal Medicine Magdeburg, Germany)
 n = 2196 extended European haplotypes logged in the database




<http://www.ystr.org/europe/>




HIV life cycle



Natural history of HIV infection




Correlation between HIV load in plasma and progression to AIDS




The HIV viral load is helpful in several areas:

- The test can be used for **diagnosis**, because it can detect a viral load a few days after HIV infection. This is better than the standard HIV (antibody) test, which can be "negative" for 2 to 6 months after HIV infection.
- For **prognosis**, viral load can help predict how long someone will stay healthy. The higher the viral load, the faster HIV disease progresses.
- For **prevention**, viral load predicts how easy it is to transmit HIV to someone else. The higher the viral load, the higher the risk of transmitting HIV.
- Finally, the viral load test is valuable for **managing therapy**, to see if antiretroviral drugs are controlling the virus. Current guidelines suggest measuring baseline (pre-treatment) viral load. A drug is "working" if it lowers viral load by at least 90% within 8 weeks. The viral load should continue to drop to less than 50 copies within 6 months. The viral load should be measured within 2 to 8 weeks after treatment is started or changed, and every 3 to 4 months after that.




Potential end-points of HIV-vaccine efficacy trials



Genetic Engineering

- Recombinant proteins
- Genetically modified plants
- Genetically modified animals
- Gene therapy
- Gene editing



Restriction enzymes

The Nobel Prize in Physiology or Medicine 1978
Werner Arber, Daniel Nathans, Hamilton O. Smith


The Nobel Prize in Physiology or Medicine 1978
Nobel Prize Award Ceremony

Werner Arber
Biographical: Nobel Lecture, Interview, Other Resources

Daniel Nathans
Biographical: Nobel Lecture, Banquet Speech

Hamilton O. Smith
Biographical: Nobel Lecture, Interview


Recombinant DNA molecules




Genetic Engineering

- Recombinant proteins
- Genetically modified plants
- Genetically modified animals
- Gene therapy
- Gene editing

Recombinant DNA technology



cDNA




Biopharmaceutical Products

Product	Product
Insulin	1982
Human Growth Hormone (hGH)	1985
α-Interferon	1986
Hepatitis B Vaccine	1986
Tissue Plasminogen Activator (TPA)	1987
Erythropoietin-α	1989
γ-Interferon	1990
Granulocyte Colony Stimulating Factor (G-CSF)	1991
Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)	1991
Interleukin 2	1992
Factor VIII	1992
β-Interferon	1993
DNase (Pulmozyme®)	1993
Glucocerebrosidase (Cerezyme®)	1994
ReoPro®	1994

Source: Consulting Resources Corp.


The 3D structure of a protein kinase



The ATP (which donates the P group) and the substrate are held in the active site, between the orange and yellow loops


DISCOVERIES LEADING TO FDA APPROVAL OF STI571/Gleevec FOR TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA

- 1960** - Abnormal chromosome 22 (Philadelphia Chromosome) observed in CML patients
- 1970** - Chromosome 22 and 9 translocation observed by new staining techniques
- 1980** - *abl* Proto-oncogene identified in chromosome 22 translocation
- 1984-1987** - BCR-ABL protein identified as possible cause of CML
- 1990** - *bcr-abl* Gene identified as cause of leukemia in mice
- 1993** - First STI571/Gleevec laboratory studies begin
- 1998** - First human tests begin
- 1999** - First human results reported
- 2000** - **2001 - April:** Larger study confirms earlier findings
- 2001 - May:** FDA approves STI571/Gleevec for treatment for CML






Clinical Trials for STI571 Have Mushroomed Since Early 1999

After success with a small Phase I clinical trial to test the safety of STI571 (Gleevec™) for treating chronic myelogenous leukemia, clinical investigators began testing the drug in a variety of cancers that share common molecular abnormalities. A rapid and broad expansion of clinical trials followed.



Tyrosine kinase inhibitors

Tyrosine kinase inhibitors are also called TKIs. They block chemical messengers (enzymes) called tyrosine kinases. Tyrosine kinases help to send growth signals in cells. So blocking them stops the cell growing and dividing. Cancer growth blockers can block one type of tyrosine kinase or more than one type. TKIs that block more than one type of tyrosine kinase are called multi-TKIs.



TKIs Approved for Clinical Use

- Herceptin (trastuzumab) - metastatic breast cancer
- Gleevec (imatinib) - chronic myeloid leukaemia and GIST
- Irressa (gefitinib) - NSCLC
- Erbitux (cetuximab) - metastatic colorectal cancer
- Tareeva (erlotinib) - NSCLC

Genetic Engineering

- Recombinant proteins
- Genetically modified plants
- Genetically modified animals
- Gene therapy
- Gene editing




Many crops never existed in nature



Seedless fruits are not natural



More than one way to alter a plant





Nutritionally Enhanced: Golden Rice

Vitamin A deficiency is a leading cause of blindness often leading to mortality throughout the developing world.

Without vitamin A proper development does not take place and 2 million children die by the age of 4 or 5 every year.

Many more children die from vitamin A deficiency than from AIDS, tuberculosis or malaria.



The solution: golden rice, engineered to produce beta-carotene, the precursor of vitamin A



La patata in Australia



PLRV (Potato Leaf Roll Virus) e' il principale problema per le coltivazioni di patate in Australia

Inserendo un gene di PLRV la patata diventa resistente all'infezione



Trasporto e lavorazione innescano un processo di ossidazione che conferisce alle patate uno sgradevole colore bruno

Tale processo può essere prevenuto inserendo una copia antisense del gene responsabile, la PPO (polifenol-ossidasi)



Le patate geneticamente modificate, resistenti all'infezione da PRLV e all'ossidazione, sono disponibili sul mercato australiano dall'anno 2000

In Europa ad un acceso dibattito intorno ai rischi degli OGM non corrisponde una adeguata conoscenza del problema dal punto di vista scientifico



- 35% della persone intervistate ritiene che i pomodori non contengono geni, mentre li contengono soltanto quelli geneticamente modificati


- il 24% ritiene che "Se una persona mangia OGM I geni si trasferiscano a lui"

Eurobarometer Survey, 2000




Salinity and drought: two serious threats to agricultural yield

NASA satellites unlock secret to Northern India's vanishing water




Haryana, Punjab, Rajasthan and Delhi (the grain baskets of India) lost 109 cubic km of ground water in last 6 yrs (2002-08)



Shesh L Singla-Pareek ICGEB, New Delhi

Triple transgenic rice plants for durable stress tolerance



Triple (GlyI+GlyII+NHX) transgenic rice plants show better reproductive growth as compared to double (GlyI+GlyII) or single (NHX1) transgenic lines and WT plants under salinity stress conditions


Shesh L Singla-Pareek ICGEB, New Delhi

Biological pesticides for pest control



Biopesticide based on insect symbiont bacteria for agriculture and horticultural crops developed and commercialised, over 300,000 litres /year

Biopesticides




Genetic engineering for biofuel production

Biofuels provide a potential route to avoiding the global political instability and environmental issues that arise from reliance on petroleum. Currently, most biofuel is in the form of **ethanol** generated from **starch or sugar** (Brazil supplies one quarter of its ground transportation fuel with ethanol from the fermentation of sugarcane sugar), but this can meet only a limited fraction of global fuel requirements. In addition, starch and sugar that are used for the production of ethanol compete with food supplies.

Conversion of **cellulosic biomass**, which is both abundant and renewable, is a promising alternative. However, the cellulases and pretreatment processes involved are very expensive. **Genetically engineering plants to produce cellulases and hemicellulases**, and to reduce the need for pretreatment processes through lignin modification, are promising paths to solving this problem, together with other strategies, such as increasing plant polysaccharide content and overall biomass.



Genetically modified mosquitoes to combat Zika virus



Aedes mosquito transmits Zika, dengue, yellow fever and chikungunya

Big companies and GMOs



Mixed Messages

Faced with protests over genetically modified foods, some major food companies are divided over how to deal with the controversy.

GENETICALLY MODIFIED CROPS ARE NOW WIDELY GROWN

Soybeans 52% genetically modified
38 million acres out of 72 million total acres in the United States

Corn 25% genetically modified
19 million acres out of 76 million total acres in the United States

... AND COMPANIES FACE MORE CONFLICTS

NOVARTIS
ONE SIDE: Gerber Products, a unit of the company, has banned genetically modified ingredients from its baby-food formulas.
THE OTHER SIDE: Novartis is a Swiss pharmaceutical giant that makes and sells genetically modified corn and soybean seeds.



PEPSICO
ONE SIDE: The Frito-Lay division announced in January that it would stop using genetically modified corn in its chips.
THE OTHER SIDE: The company's flagship soft drink uses corn syrup made from genetically modified corn.



MCDONALD'S
ONE SIDE: Asked suppliers to stop shipping genetically modified potatoes.
THE OTHER SIDE: In its restaurants, French fries are cooked in vegetable oil made from genetically modified corn and soybeans.

Conceptual paper
The Nobel Laureates' Campaign Supporting GMOs

Richard J. Roberts

New England Biolabs, Inc., 240 County Road, Ipswich, MA 01938, USA



ARTICLE INFO

Article history:
Received 13 December 2017
Accepted 13 December 2017
Available online 27 March 2018

Keywords:
GMO
Hunger
Nutrition
Crop
Pest
Food
Precision agriculture


ABSTRACT

More than 800 million people suffer from hunger in the world. Using modern plant breeding methods to generate so-called GMOs (Genetically Modified Organisms), agricultural scientists have shown that crop yields and nutritional quality can be greatly improved. Many GMO varieties have been specifically developed with the aim of being resistant to pests, tolerant to drought and containing beneficial nutrients. This leads to a reduction in the use of insecticides in water and on land. If anything, the GMO varieties are safer than traditionally bred varieties because they are made in a very precise manner. However, the scientific evidence on this issue is being ignored by the Green Parties such as Greenpeace who continue to deny the science and mislead the public. 129 Nobel Laureates have joined in a campaign to convince the Green Parties and the public that they should support the use of GMOs, especially for the sake of the developing world.

© 2018 Journal of Innovation & Knowledge. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Genetic Engineering

- Recombinant proteins
- Genetically modified plants
- Genetically modified animals
- Gene therapy
- Gene editing




Genetic manipulation of animals to discover gene function



Drosophila melanogaster

When flies have a mutation wherein the *Antennapedia* gene is expressed in the head (as well as in the thorax), legs rather than antennae grow out of the head sockets

How to make a transgenic mouse




Transgenesis involves transfer of foreign DNA into totipotent or pluripotent embryo cells (either fertilized oocytes, cells of the very early embryo or cultured embryonic stem cells) followed by insertion of the transferred DNA into host chromosomes


Transgenic mouse for growth hormone



Green fluorescent protein



238-amino-acids 27-kD protein containing a photoexcitable greenish-light-emitting chromophore



The GFP transgenic mouse



The Green Fluorescent Protein (GFP) from the *Aequora victoria* jellyfish

Genetic Engineering

- Recombinant proteins
- Genetically modified plants
- Genetically modified animals
- Gene therapy
- Gene editing

la Repubblica

L'Aifa approva il medicinale più caro della storia: lo Zolgensma contro la Sma di Michele Bocci



Negli Usa ha avuto il via libera per 2.1 milioni di dollari. In Italia si sarebbe raggiunto un accordo con Novartis, per riconoscere circa 1.5 milioni di euro a trattamento ma prevedendo un pagamento dilazionato nel tempo

10 MARZO 2021

1 MINUTI DI LETTURA

Currently approved gene therapy products

Drug	Company	Disease	Prevalence	Price (USD)
Glybera	UniQure	Lipoprotein lipase deficiency (LPLD)	1:1,000,000	1M
Strimvelis	GlaxoSmithKline	ADA-SCID	1:100,000	665K (money-back)
Yescarta	Gilead/Kite Pharma	CAR-T for Diffuse Large B-cell NHL	4:100,000 per year	373K
Kymriah	Novartis	CAR-T for B-cell ALL	1,7:100,000	475K
Luxturna	Spark Therapeutics	LCA due to RPE65 defects	<1:100,000	435K per eye
Zynteglo	Bluebird bio	Beta thalassaemia	60K symptomatic individuals born annually	1.78M (over 5 years)
Zolgensma	Avexis/Novartis	SMA	1-2:100,000	2.1M

Genetic Engineering

- Recombinant proteins
- Genetically modified plants
- Genetically modified animals
- Gene therapy
- Gene editing

Genetic engineering: fear and worry

